Portal Hypertension in Cirrhosis: The 2026 GESA Consensus Explained for GPs
Australia's gastroenterology community has produced the first nationally specific, evidence-based consensus on how to diagnose and manage portal hypertension in cirrhosis. Published in Hepatology Communications April 2026, the statement was developed by GESA with input from 46 clinicians spanning hepatology, gastroenterology, interventional radiology, surgery, dietetics, and exercise physiology. It delivers 52 GRADE-rated recommendations across nine domains.
For GPs, several of these recommendations reflect shifts in best practice. What follows is a summary of the most clinically relevant changes.
The burden of chronic liver disease in Australia
Liver disease has historically been underappreciated as a cause of premature mortality in this country. That framing is now hard to sustain. According to the Australian Burden of Disease Study 2024 chronic liver disease ranks as the third leading cause of premature death in Australians aged 50 to 59, and the fourth leading cause across every five-year age group from 35 to 70. The gap in outcomes for Indigenous Australians is stark: the standardised death rate from chronic liver disease is close to three times higher than in non-Indigenous Australians.
The driver of this rising burden is predominantly MASLD, metabolic dysfunction-associated steatotic liver disease, which is tightly linked to obesity, type 2 diabetes, and metabolic syndrome. Cirrhosis is estimated to affect around 1 in 200 Australians, although this may be an underestimation.
The practical implication for general practice is straightforward: patients with metabolic risk factors and abnormal liver function tests warrant earlier and more systematic evaluation than has historically been the norm.
Diagnosing cirrhosis and portal hypertension without biopsy
Liver biopsy as a routine diagnostic tool for confirming cirrhosis has been superseded. The consensus is clear on this point, recommending a combination of clinical assessment, serum-based non-invasive tests, and elastography as the primary pathway.
FIB-4, APRI, and transient elastography (FibroScan) combined with platelet count form the practical toolkit for most patients, with the Baveno consensus statement "rule of 5" liver stiffness thresholds providing a structured framework for interpreting FibroScan results across common aetiologies.
For GPs, FIB-4 and platelet count, derivable from a standard blood panel, are a sensible starting point in any patient where chronic liver disease is suspected. Abnormal results (Fib-4 > 1.3) justify timely specialist referral for elastography-based assessment before advanced fibrosis is established.
Variceal screening: endoscopy is now more targeted
Prior practice involved broader endoscopic surveillance of patients with cirrhosis. The consensus narrows this considerably, with two recommendations that together reduce the number of patients who need routine endoscopy:
"Patients with compensated cirrhosis and clinically significant portal hypertension (CSPH) who are not candidates for non-selective beta-blocker (NSBB) therapy should undergo an upper gastrointestinal endoscopy and variceal band ligation of high-risk esophageal varices. Quality of evidence: Moderate; Strength of recommendation: Strong"
"In patients with compensated cirrhosis where CSPH has been ruled out, screening endoscopy for the detection of varices should be avoided. Quality of evidence: Moderate; Strength of recommendation: Strong"
In practical terms, patients who have clinically significant portal hypertension (CSPH) excluded non-invasively do not need endoscopy. Patients who are tolerating target doses of carvedilol do not need routine surveillance endoscopy either. The emphasis has shifted toward accurate non-invasive characterisation of portal pressure status as the decision-making anchor.
Carvedilol is now the preferred non-selective beta-blocker
Propranolol has been the default NSBB in portal hypertension management for decades. The consensus now explicitly favours carvedilol, at a target dose of 12.5 mg daily:
"Patients with compensated cirrhosis and CSPH should be considered for treatment with carvedilol to reduce the risk of hepatic decompensation. Quality of evidence: High; Strength of recommendation: Strong"
The rationale is carvedilol's additional alpha-1 adrenergic blockade on intrahepatic resistance, which is thought to underpin both its better tolerability and its efficacy at lower doses compared to propranolol. The PREDESCI trial, which provided the primary evidence base for NSBB use in compensated cirrhosis with CSPH, reported a number needed to treat of 9 to prevent one episode of death or decompensation, a clinically meaningful effect that makes accurate identification of CSPH important to avoid over treatment.
NSBBs should not be started and should be discontinued in patients with refractory ascites who have persistently low blood pressure or hepatorenal syndrome-AKI, per recommendation 24.
Primary Spontaneous Bacterial Peritonitis prophylaxis: no longer recommended
This is perhaps the most straightforward practice change in the consensus:
"In general, primary antibiotic prophylaxis to prevent spontaneous bacterial peritonitis (SBP) is not recommended. Quality of evidence: Moderate; Strength of recommendation: Strong"
The reversal reflects accumulating evidence that primary prophylaxis offers limited benefit in most patient groups while contributing to the emergence of multidrug-resistant organisms, a problem that is increasingly consequential in patients with decompensated cirrhosis.
Secondary prophylaxis following a first episode of SBP remains recommended, using norfloxacin or trimethoprim-sulfamethoxazole, with the consensus noting ongoing concerns about antibiotic resistance in this context as well.
Anticoagulation in cirrhosis: DOACs are now first-line
The historical reluctance to anticoagulate patients with cirrhosis, on the basis of already abnormal coagulation indices, has been substantially revised. The IMPORTAL meta-analysis demonstrated that anticoagulation for portal vein thrombosis was associated with reduced all-cause mortality independently of thrombus recanalization, providing a clear rationale for a lower threshold to treat.
"For patients with cirrhosis and new portal vein thrombosis, anticoagulation should be considered to reduce the risk of liver-related events and mortality. Quality of evidence: Moderate; Strength of recommendation: Strong"
"For patients with cirrhosis (Child–Pugh class A or B) and portal hypertension requiring anticoagulation, direct-acting anticoagulants should be considered safe and effective alternatives to warfarin and low-molecular-weight heparin. Quality of evidence: Low-moderate; Strength of recommendation: Strong"
Of the available DOACs, apixaban is preferred on the basis of its lower bleeding risk profile in cirrhosis. Child–Pugh C patients requiring anticoagulation should be managed with specialist haematology input given the complexity of coagulation in advanced disease.
Hepatic encephalopathy: stop measuring ammonia
"Routine measurement of plasma ammonia level is not recommended for the diagnosis and monitoring of hepatic encephalopathy (HE) in patients with CLD. Quality of evidence: Moderate; Strength of recommendation: Strong"
Despite widespread use, plasma ammonia adds little diagnostic value in HE and should not drive clinical decision-making. Psychometric tools are the preferred diagnostic modality, with the animal naming test and QuickStroop highlighted as practical options that can be completed in under a minute, relevant for both specialist and general practice settings.
Lactulose remains first-line treatment for overt HE. Rifaximin 550 mg twice daily is recommended as an adjunct when lactulose has failed or is not tolerated, and for secondary prevention of overt HE episodes. Its lack of systemic absorption makes it suitable for long-term use.
Pregnancy and cirrhosis: pre-conception planning is essential
"Women with cirrhosis who are planning to become pregnant should undergo assessment of liver disease severity, including upper gastrointestinal endoscopy, and be offered appropriate pre-pregnancy counselling. Quality of evidence: Low; Strength of recommendation: Strong"
"If endoscopy has not been performed within 1 year of conception, upper gastrointestinal endoscopy in the second trimester of pregnancy is recommended for women with cirrhosis and portal hypertension. Quality of evidence: Low; Strength of recommendation: Strong"
Pregnancy in women with cirrhosis carries real risk. Registry data show that decompensation occurs in up to 21% of pregnancies in women with cirrhosis, with variceal bleeding occurring in up to 16%. A preconception MELD score of 10 or above is associated with significantly increased decompensation risk during pregnancy.
GPs are well placed to identify women of reproductive age with cirrhosis or advanced fibrosis and ensure they receive pre-conception hepatology review before pregnancy rather than during it.
Summary for practice
The 2026 GESA consensus represents a consolidation of evidence that has been accumulating for several years, now formalised into Australian-specific guidance. The changes most relevant to general practice are:
- Non-invasive testing has replaced liver biopsy as the primary diagnostic pathway for cirrhosis and CSPH.
- Variceal surveillance endoscopy is now more selective.
- Carvedilol at 12.5 mg daily has replaced propranolol as the preferred NSBB.
- Primary SBP prophylaxis is no longer recommended.
- DOACs, particularly apixaban, are first-line for anticoagulation in Child–Pugh A and B cirrhosis.
- Plasma ammonia should not be used to diagnose or grade hepatic encephalopathy.
- And women with cirrhosis planning pregnancy benefit substantially from specialist assessment before conception.
The full consensus statement is available here.
For patients in your practice with suspected or established chronic liver disease, unexplained liver function test abnormalities, or metabolic risk factors warranting specialist assessment, we welcome referrals to Carlton Specialists.
